secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001193125-25-073991
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M
------------------------------------------------------------------------------

- Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.
- PRV granted by FDA in Sept 2024 following approval of MIPLYFFA for Niemann-Pick disease type C.
- Unaudited cash, cash equivalents and investments at Mar 31, 2025 were $68.7M.
- Pro forma cash after net proceeds of $148.3M is $217M; CFO cites support for MIPLYFFA and OLPRUVA launches and celiprolol Phase 3 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000119312525073991/0001193125-25-073991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000119312525073991/d938703d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-073991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer